Role of the costimulatory molecule CD28 in the development of lupus in MRL/lpr mice

Journal of Immunology

Volumn 163, Issue 6, 1999, Pages 3153-3159

  Tada, Yoshifumi ^a   Nagasawa, Kohei ^a   Ho, Alexandra ^b   Morito, Fumitaka ^a   Koarada, Syuichi ^a   Ushiyama, Osamu ^a   Suzuki, Noriaki ^a   Ohta, Akihide ^a   Mak, Tak W ^b,c  

^a SAGA UNIVERSITY   (Japan)

^b UNIVERSITY OF TORONTO   (Canada)

^c AMGEN INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD28 ANTIGEN; DNA ANTIBODY; IMMUNOGLOBULIN G; RHEUMATOID FACTOR;

ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; GENE TARGETING; GLOMERULONEPHRITIS; HYPERGAMMAGLOBULINEMIA; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLENOMEGALY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIGENS, CD28; FEMALE; GLOMERULAR MESANGIUM; IMMUNOGLOBULINS; LUPUS NEPHRITIS; LYMPHATIC DISEASES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MICE; MICE, INBRED MRL LPR; MICE, KNOCKOUT; SPLENOMEGALY;

EID: 0033568177     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Cohen, P. L., and R. A. Eisenberg. 1991. lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu. Rev. Immunol. 9:243.
2. Theofilopuolos, A. N., and F. J. Dixon. 1985. Murine models of systemic lupus erythematosus. Adv. Immunol. 37:269.
3. Andrews, B. S., R. A. Eisenberg, A. N. Theofilopoulos, S. Izui, C. B. Wilson, P. J. McConahey, E. D. Murphy, J. B. Roths, and F. J. Dixon. 1978. Spontaneous murine lupus-like syndromes: clinical and immunopathological manifestations in several strains. J. Exp. Med. 148:1198.
4. Watanabe-Fukunaga, R., C. I. Brannan, N. G. Copeland, N. A. Jenkins, and S. Nagata. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314.
5. Watson, M. L., J. K. Rao, G. S. Gilkeson, P. Ruiz, E. M. Eicher, D. S. Pisetsky, A. Matsuzawa, J. M. Rochelle, and M. F. Seldin. 1992. Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestation and renal disease-modifying loci. J. Exp. Med. 176:1645.
6. Russell, J. H., B. Rush, C. Weaver, and R. Wang. 1993. Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc. Natl. Acad. Sci. USA 90:4409.
7. + T lymphocytes from MRL/lpr mice are resistant to receptor-mediated tolerance and apoptosis. J. Immunol. 151:7233.
8. + T cells to lymphoproliferation and autoantibody production in MRL-lpr/lpr mice. J. Exp. Med. 167:1713.
9. O'Sullivan, F. X., C. J. Ray, Y. Takeda, G. C. Sharp, and S. E. Walker. 1991. Long-term anti-CD4 treatment of MRL/lpr mice ameliorates immunopathology and lymphoproliferation but fails to suppress rheumatoid factor production. Clin. Immunol. Immunopathol. 61:421.
10. Jabs, D. A., C. L. Burek, Q. Hu, R. C. Kuppers, B. Lee, and R. A. Prendergast. 1992. Anti-CD4 monoclonal antibody therapy suppresses autoimmune diseases in MRL/Mp-lpr/lpr mice. Cell. Immunol. 141:496.
11. 1 and MRL/MpJ-lpr/lpr mice. J. Immunol. 151:6509.
12. Henrickson, M., E. H. Giannini, and R. Hirsch. 1994. Reduction of mortality and lymphoadenopathy in MRL-lpr/lpr mice treated with nonmitogenic anti-CD3 monoclonal antibody. Arthritis Rheum. 37:587.
13. Seaman, W. E., D. Wofsy, J. S. Greenspan, and J. A. Ledbetter. 1983. Treatment of autoimmune MRL/lpr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal disease. J. Immunol. 130:1713.
14. Mountz, J. D., H. R. Smith, R. L. Wilder, J. P. Reeves, and A. D. Steinberg. 1987. CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production. J. Immunol. 138:157.
15. Koh, D.-R., A. Ho, A. Rahemtulla, W.-P. Fung-Leung, H. Griesser, and T. W. Mak. 1995. Murine lupus in MRL/lpr mice lacking CD4 or CD8 T cells. Eur. J. Immunol. 25:2558.
16. Jevnikar, A. M., M. J. Grusby, and L. H. Glimcher. 1994. Prevention of nephritis in major histocompatibility complex class II-deficient MRL-lpr mice. J. Exp. Med. 179:1137.
17. + T cells but normal autoantibody production in lpr/lpr mice lacking major histocompatibility complex class I molecule. Eur. J. Immunol. 25:37.
18. 2-microglobulin. J. Immunol. 154:2063.
19. Maldonado, M. A., R. A. Eisenberg, E. Roper, P. L. Cohen, and B. L. Kotzin. 1995. Greatly reduced lymphoproliferation in lpr mice lacking major histocompatibility complex class I. J. Exp. Med. 181:641.
20. 2-Microglobulin dependence of the lupus-like autoimmune syndrome of MRL-lpr mice. J. Immunol. 156:4932.
21. Peng, S. L., M. P. Madaio, D. P. M. Hughes, I. N. Crispe, M. J. Owen, L. Wen, A. C. Hayday, and J. Craft. 1996. Murine lupus in the absence of aβ T cells. J. Immunol. 156:4041.
22. Bretscher, P. 1992. The two-signal model of lymphocyte activation twenty-one years later. Immunol. Today 13:74.
23. Linsey, P. S., and J. A. Ledbetter. 1993. The role of the CD28 receptor during T-cell responses to antigen. Annu. Rev. Immunol. 11:191.
24. June, C. H., J. A. Bluestone, L. M. Nadler, and C. B. Thompson. 1994. The B7 and CD28 receptor families. Immunol. Today 15:321.
25. Harding, F. A., J. G. McArthur, J. A. Gross, D. H. Raulet, and J. P. Allison. 1992. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607.
26. Finck, B. K., P. S. Linsley, and D. Wolfy. 1994. Treatment of murine lupus with CTLA4Ig. Science 265:1225.
27. Lenschow, D. J., S. C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K. C. Herold, and J. A. Bluestone. 1995. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181:1145.
28. Cross, A. H., T. J. Girard, K. S. Giacoletto, R. J. Evans, R. M. Keeling, R. F. Lin, J. L. Trotter, and R. W. Karr. 1995. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J. Clin. Invest. 95:2783.
29. Arima, T., A. Rehman, W. F. Hickey, and M. W. Flye. 1996. Inhibition by CTLA4Ig of experimental allergic encephalomyelitis. J. Immunol. 156:4916.
30. Knoerzer, D. B., R. W. Karr, B. D. Schwartz, and L. J. Mengle-Gaw. 1995. Collagen-induced arthritis in the BB rat. Prevention of diseases by treatment with CTLA-4-Ig. J. Clin. Invest. 96:987.
31. Webb, L. M. C., M. J. Walmsley, and M. Feldmann. 1996. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur. J. Immunol. 26:2320.
32. Shahinian, A., K. Pfeffer, K. P. Lee, T. M. Kündig, K. Kishihara, A. Wakeham, K. Kawai, P. S. Ohashi, C. B. Thompson, and T. W. Mak. 1993. Differential T cell costimulatory requirements in CD28-deficient mice. Science 261:609.
33. Mountz, J. D., W. C. Gause, F. D. Finkelman, A. D. Steinberg. 1988. Prevention of lymphadenopathy in MRL-lpr/lpr mice by blocking peripheral lymph node homing with Mel-14 in vivo. J. Immunol. 140:2943.
34. Ishigatsubo, Y., A. D. Steinberg, and D. M. Klinman. 1988. Autoantibody production is associated with polyclonal B cell activation in autoimmune mice which express the lpr or gld genes. Eur. J. Immunol. 18:1089.
35. Perkins, D. L., R. M. Glaser, C. A. Mahon, J. Michaelson, and A. Marshak-Rothstein. 1990. Evidence for an intrinsic B cell defect in lpr/lpr mice apparent in neonatal chimeras. J. Immunol. 145:549.
36. Sobel, E. S., T. Katagiri, K. Katagiri, S. C. Morris, P. L. Cohen, and R. A. Eisenberg. 1991. An intrinsic B cell defect is required for the production of autoantibodies in the lpr model of murine systemic autoimmunity. J. Exp. Med. 173:1441.
37. Linsley, P. S., P. M. Wallace, J. Johnson, M. G. Gibson, J. L. Greene, J. A. Ledbetter, C. Singh, and M. A. Tepper. 1992. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257:789.
38. Dang, H., and R. J. Harbeck. 1984. The in vivo and in vitro glomerular deposition of isolated anti-double stranded-DNA antibodies in NZB/W mice. Clin. Immunol. Immunopathol. 30:265.
39. Madaio, M. P., J. Carlson, J. Cataldo, A. Ucci, P. Migliorini, and O. Pankewycz. 1987. Murine monoclonal anti-DNA antibodies bind directly to glomerular antigens and form immune deposits. J. Immunol. 138:2883.
40. Vlahakos, D. V., M. H. Foster, S. Adams, M. Katz, A. A. Ucci, K. J. Barrett, S. K. Datta, and M. P. Madaio. 1992. Anti-DNA antibodies from immune deposits at distinct glomerular and vascular sites. Kidney Int. 41:1690.
41. Shlomchik, M. J., M. P. Madaio, D. Ni, M. Trounstein, and D. Huszar. 1994. The role of B cells in lpr/lpr-induced autoimmunity. J. Exp. Med. 180:1295.
42. Germann, T., M. Bongartz, H. Dlugonska, H. Hess, E. Schmitt, L. Kolbe, E. Kolsch, F. J. Podlaski, M. K. Gately, and E. Rüde. 1995. Interleukin-12 pro-foundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur. J. Immunol. 25:823.
43. Reininger, L., T. Berney, T. Shibata, F. Spertini, R. Merino, and S. Izui. 1990. Cryoglobulinemia induced by a murine IgG3 rheumatoid factor: skin vasculitis and glomerulonephritis arise from distinct pathogenic mechanisms. Proc. Natl. Acad. Sci. USA 87:10038.
44. Takahashi, S., M. Nose, J. Sasaki, T. Yamamoto, and M. Kyogoku. 1991. IgG3 production in MRL/lpr mice is responsible for development of lupus nephritis. J. Immunol. 147:515.
45. Berney, T., T. Fulpius, T. Shibata, L Reininger, J. Van-Snick, H. Shan, M. Weigert, A. Marshak-Rothstein, and S. Izui. 1992. Selective pathogenicity of murine rheumatoid factors of the cryoprecipitable IgG3 subclass. Int. Immunol. 4:93.
46. Lemoine, R., T. Berney, T. Shibata, T. Fulpius, Y. Kyogoku, H. Shimada, S. Sawada, and S. Izui. 1992. Induction of "wire-loop" lesions by murine monoclonal IgG3 cryoglobulins. Kidney Int. 41:65.
47. Chesnutt, M. S., B. K. Finck, N. Killeen, M. K. Connolly, H. Goodman, and D. Wofsy. 1998, Enhanced lymphoproliferation and diminished autoimmunity in CD4-deflcient MRL/lpr mice. Clin. Immunol. Immunopathol. 87:23.
48. Gilkeson, G. S., J. S. Mudgett, M. F. Seldin, P. Ruiz, A. A. Alexander, M. A. Misukonis, D. S. Pisetsky, and B. Weinberg. 1997. Clinical and serologic manifestations of autoimmune disease in MRL-lpr/lpr mice lacking nitric oxide synthase type 2. J. Exp. Med. 186:365.
49. Moyer, C. F., J. D. Strandberg, and C. L. Reinisch. 1987. Systemic mononuclear-cell vasculitis in MRL/Mp-lpr/lpr mice: a histologic and immunocytochemical analysis. Am. J. Pathol. 127:229.
50. Nose, M., M. Nishimura, and M. Kyogoku. 1989. Analysis of granulomatous arteritis in MRL/Mp autoimmune disease mice bearing lymphoproliferative genes: the use of mouse genetics to dissociate the development of arteritis and glomerulonephritis. Am. J. Pathol. 135:271.
51. Nose, M., M. Nishimura, M. R. Ito, J. Toh, T. Shibata, and T. Sugisaki. 1996. Arteritis in a novel congenic strain of mice derived from MRL/lpr lupus mice: genetic dissociation from glomerulonephritis and limited autoantibody production. Am. J. Pathol. 149:1763.
52. Lenschow, D. J., K. C. Herold, L. Rhee, B. Patel, A. Koons, H.-Y. Qin, E. Fuchs, B. Singh, C. B. Thompson, and J. A. Bluestone. 1996. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 5:285.